Skip to main content

Advertisement

Table 3 Median overall survival from the time of hypofractionated stereotactic radiotherapy (HFSRT) in subgroups of patients with recurrent malignant glioma.

From: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

  n median (range) overall survival (months) p
WHO grade (initial histopathology)    
II or III 10 13.5 (1.9–77.6) 0.036
IV 9 7.4 (4.2–10.8)  
WHO grade (most recent before HFSRT)    
III 5 15.4 (1.9–77.6) 0.029
IV 14 7.9 (4.2–38.8)  
initial surgical procedure    
biopsy 15 9.3 (4.2–77.6) 0.89
resection 4 9.2 (1.9–34.6)  
chemotherapy before HFSRT    
yes 13 9.3 (1.9–77.6) 0.76
no 6 8.9 (7.3–15.4)  
reoperation before HFSRT    
yes 12 8.4 (1.9–77.6) 0.93
no 7 9.3 (5.6–34.6)  
age at time of HFSRT    
< 50 years 11 11.9 (1.9–77.6) 0.14
> 50 years 8 8.9 (5.0–11.1)  
Karnofsky performance score at time of HFSRT    
≥ 90 14 7.9 (4.2–77.6) 0.80
< 90 5 11.9 (1.9–15.4)  
planning target volume (ml)    
< 15 ml 9 9.3 (5.2–38.8) 0.59
> 15 ml 10 7.4 (1.9–77.6)  
interval first RT series to HFSRT    
> 20 months 9 7.4 (1.9–77.6) 0.90
< 20 months 10 9.3 (5.6–38.8)  
total HFSRT dose    
30 Gy 11 11.1 (1.9–77.6) 0.051
< 30 Gy 8 7.4 (4.2–11.9)  
chemotherapy after HFSRT    
yes 13 9.3 (1.9–77.6) 0.27
no 6 8.9 (4.2–11.1)